Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Fig. 1

Change from baseline in systolic blood pressure at Week 40/42. Data are least-squares mean ± SE. Pooled comparator data are not presented as these comparators have varying effects on SBP. Data are taken from the safety population of each study. *p < 0.05 vs. placebo/active comparator, ***p < 0.001 vs. placebo/active comparator. CI confidence interval, SBP systolic blood pressure, SE standard error, TZP tirzepatide

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840